All In Biotech

Drug Trial Radar · NCT04440735

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)

Last checked: Nov 19, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Oct 7, 2020

Primary completion

Sep 2025

Study completion Sep 2025

Sponsor

Lead sponsor
Kahr MedicalIndustry
Sponsor type
Industry
First posted
Jun 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.

Conditions

  • Advanced Solid Tumor
  • Non Small Cell Lung Cancer
  • Colorectal Cancer

Interventions

  • DSP107Biological

    DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

  • AtezolizumabBiological

    Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: Duration of the study, estimated to be 9 months
  2. Dose Limiting Toxicities (DLT)Time frame: At the end of Treatment Cycle 1 (each cycle is 21 days)
  3. DSP107 Serum ConcentrationTime frame: At the end of Treatment Cycle 8 (each cycle is 21 days)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Moores Cancer Center, UCSD

    La Jolla, California

  • University of Colorado Hospital, Anschutz Cancer Pavilion (ACP)

    Aurora, Colorado

  • Florida Cancer Specialists

    Lake Mary, Florida

  • Indiana University Simon Cancer Center

    Indianapolis, Indiana

  • KUCC / KUMCRI University of Kansas Cancer Center

    Kansas City, Kansas

  • SKCC-Sidney Kimmel Cancer Center Thomas Jefferson University

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center University of Pittsburgh

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.